NCT03214380

Who might be able to join this trial:

• You have been diagnosed with type 2 diabetes (based on World Health Organization guidelines) for at least 1 year before the screening visit.
• You have been using a long-acting (basal) insulin plus at least one mealtime (bolus) insulin injection for at least 90 days before screening, OR you have been using a premixed insulin injected at least twice daily for at least 90 days before screening.
• You may also be taking up to 3 of the following diabetes pills: metformin, a DPP-4 inhibitor, an SGLT2 inhibitor, a sulfonylurea, a meglitinide, or an alpha-glucoside inhibitor (confirm with trial site if you are unsure which category your medication falls into).
• Your HbA1c blood sugar level (a measure of average blood sugar over roughly 3 months) is between 7.0% and 10.0% at the time of screening.
• Your body mass index (BMI — a measure based on your height and weight) is 45.0 or below at the time of screening.

Who may not be able to join:

• You have ever been diagnosed with type 1 diabetes or a condition called Latent Autoimmune Diabetes in Adults (LADA).
• You are unable to feel the warning signs of low blood sugar (a condition called hypoglycemia unawareness), as assessed by the study doctor.
• You have had a severe low blood sugar episode in the 6 months before screening.
• You have had one or more episodes of diabetic ketoacidosis or a serious high blood sugar emergency called hyperglycemic hyperosmolar state in the 6 months before screening.
• You have used certain diabetes medications — thiazolidinediones (such as pioglitazone), GLP-1 receptor agonists (such as semaglutide or liraglutide), or pramlintide — within 90 days before screening.

Important: Always verify eligibility with the trial site directly before applying.